Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial (Q34452976)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial (English)

1 reference

Europe PubMed Central

2 August 2017

revascularization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert D McBane

object named as

Robert D McBane

5

0 references

Maria M. Brooks

object named as

Maria M Brooks

4

0 references

9

object named as

Robert Wolk

1 reference

Europe PubMed Central

2 August 2017

author name string

Burton E Sobel

1

1 reference

Europe PubMed Central

2 August 2017

Regina M Hardison

2

1 reference

Europe PubMed Central

2 August 2017

Saul Genuth

3

1 reference

Europe PubMed Central

2 August 2017

David J Schneider

6

1 reference

Europe PubMed Central

2 August 2017

Richard E Pratley

7

1 reference

Europe PubMed Central

2 August 2017

Kurt Huber

8

1 reference

Europe PubMed Central

2 August 2017

Ashok Krishnaswami

10

1 reference

Europe PubMed Central

2 August 2017

Robert L Frye

11

1 reference

Europe PubMed Central

2 August 2017

BARI 2D Investigators

12

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

18 July 2011

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

124

1 reference

Europe PubMed Central

2 August 2017

6

1 reference

Europe PubMed Central

2 August 2017

695-703

1 reference

Europe PubMed Central

2 August 2017

Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

6 July 2018

Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220292

27 October 2018

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new perspective on the biology of C-reactive protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypotheses, Design, and Methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasminogen Activator Inhibitor 1 Expression is Regulated by the Inflammatory Mediators Interleukin-1α, Tumor Necrosis Factor-α, Transforming Growth Factor-β and Oncostatin M in Human Cardiac Myocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21768545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1161/CIRCULATIONAHA.110.014860

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34452976&oldid=1637887724"